

CITATION REPORT

List of articles citing

Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension

DOI: 10.1016/j.healun.2010.11.009

Journal of Heart and Lung Transplantation, 2011, 30, 632-43.

Source: <https://exaly.com/paper-pdf/50314358/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
87	[Tadalafil: novel aspects of phosphodiesterase-5 inhibition in the treatment of pulmonary hypertension]. <i>Archivos De Bronconeumologia</i> , 2011 , 47 Suppl 7, 26-31	0.7	
86	Pulmonary hypertension in critical care. <i>Current Opinion in Critical Care</i> , 2011 , 17, 439-48	3.5	20
85	Recent progress in the management of pulmonary hypertension. <i>Circulation Journal</i> , 2011 , 75, 1801-10	2.9	65
84	Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. <i>American Journal of Cardiology</i> , 2011 , 108, 1177-82	3	52
83	Potential for phosphodiesterase inhibitors in the management of autoimmune diseases. <i>Drug Development Research</i> , 2011 , 72, 772-778	5.1	1
82	Treatment of pulmonary arterial hypertension with targeted therapies. <i>Nature Reviews Cardiology</i> , 2011 , 8, 526-38	14.8	102
81	Medical Treatment of Pulmonary Arterial Hypertension. <i>Progress in Respiratory Research</i> , 2012 , 237-245		
80	The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 428-33	10.2	167
79	Of tangible benefits that remain unexplained: the Papworth village movement to take care of tuberculous families. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 397-8	10.2	
78	Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. <i>Journal of Clinical Pharmacology</i> , 2012 , 52, 1784-805	2.9	54
77	PDE5 inhibitor treatment options for urologic and non-urologic indications: 2012 update. <i>Current Pharmaceutical Design</i> , 2012 , 18, 5590-606	3.3	14
76	Acute effects of vardenafil on pulmonary artery responsiveness in pulmonary hypertension. <i>Scientific World Journal, The</i> , 2012 , 2012, 718279	2.2	11
75	Emerging therapies for pulmonary arterial hypertension: a review of recently completed and ongoing clinical trials. <i>Clinical Investigation</i> , 2012 , 2, 491-501		
74	The pharmacological treatment of pulmonary arterial hypertension. <i>Pharmacological Reviews</i> , 2012 , 64, 583-620	22.5	88
73	Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations. <i>Lung</i> , 2012 , 190, 573-8	2.9	13
72	Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. <i>Respiratory Medicine</i> , 2012 , 106, 730-4	2.6	20
71	Combination therapy in pulmonary arterial hypertension. <i>Cardiology</i> , 2012 , 123, 41; author reply 42	1.6	1

70	Practical considerations for the pharmacotherapy of pulmonary arterial hypertension. <i>Pharmacotherapy</i> , 2012 , 32, 838-55	5.8	11
69	Tadalafil for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 747-55	4	13
68	The 6-minute walk test in pulmonary arterial hypertension: how far is enough?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 186, 396-7	10.2	21
67	Update on pulmonary arterial hypertension in children: management strategies and clinical utility of sildenafil. <i>Pediatric Health, Medicine and Therapeutics</i> , 2012 , 59	2.5	
66	Evolving management of pediatric pulmonary arterial hypertension: impact of phosphodiesterase inhibitors. <i>Pediatric Cardiology</i> , 2013 , 34, 213-9	2.1	9
65	Macitentan and morbidity and mortality in pulmonary arterial hypertension. <i>New England Journal of Medicine</i> , 2013 , 369, 809-18	59.2	878
64	Current and future therapeutic targets for pulmonary arterial hypertension. <i>High Altitude Medicine and Biology</i> , 2013 , 14, 134-43	1.9	4
63	An update on medical therapy for pulmonary arterial hypertension. <i>Current Hypertension Reports</i> , 2013 , 15, 614-22	4.7	17
62	Pulmonary arterial hypertension. <i>Orphanet Journal of Rare Diseases</i> , 2013 , 8, 97	4.2	168
61	In the clinic. Pulmonary hypertension. <i>Annals of Internal Medicine</i> , 2013 , 158, ITC5-1 -16	8	16
60	Endothelin receptor antagonists for pulmonary arterial hypertension. <i>The Cochrane Library</i> , 2013 , CD004434	4.3	28
59	Combination therapy in pulmonary arterial hypertension. <i>Clinics in Chest Medicine</i> , 2013 , 34, 841-55	5.3	11
58	Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , 2013 , 7, 39-49	4.9	13
57	Combination therapy in the management of pulmonary arterial hypertension. <i>International Journal of Clinical Practice</i> , 2013 , 67, 13-23	2.9	16
56	The influence of alternative instruction on 6-min walk test distance. <i>Chest</i> , 2013 , 144, 1900-1905	5.3	28
55	The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2013 , 22, 487-94	9.8	30
54	Does treatment response to ambrisentan vary by pulmonary arterial hypertension severity? Implications for clinicians and for the design of future clinical trials. <i>International Journal of Clinical Practice</i> , 2014 , 68, 568-77	2.9	6
53	Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates. <i>Annals of Thoracic Medicine</i> , 2014 , 9, S1-S15	2.2	7

52	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. <i>Global Cardiology Science & Practice</i> , 2014 , 2014, 257-90	0.7	10
51	Pulmonary hypertension and breathlessness: is it a combination we can ignore?. <i>Internal Medicine Journal</i> , 2014 , 44, 114-23	1.6	4
50	Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 391-405	4.1	51
49	Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension. <i>Hypertension Research</i> , 2014 , 37, 507-12	4.7	38
48	Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. <i>Core Evidence</i> , 2015 , 10, 99-109	4.9	19
47	Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. <i>Circulation</i> , 2015 , 132, 2037-99	16.7	624
46	Effect of nocturnal oxygen and acetazolamide on exercise performance in patients with pre-capillary pulmonary hypertension and sleep-disturbed breathing: randomized, double-blind, cross-over trial. <i>European Heart Journal</i> , 2015 , 36, 615-23	9.5	40
45	Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension of different causes: phase II results from the Pulmonary Artery Denervation-1 study. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e002837	6	71
44	Sex and menopause differences in response to tadalafil: 6-minute walk distance and time to clinical worsening. <i>Pulmonary Circulation</i> , 2015 , 5, 701-6	2.7	6
43	Six-minute walk test in pulmonary arterial hypertension. <i>Anatolian Journal of Cardiology</i> , 2015 , 15, 249-54.8	5.8	34
42	Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: A meta-analysis focusing on 6MWD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015 , 32, 24-8	3.5	2
41	Use of outcome measures in pulmonary hypertension clinical trials. <i>American Heart Journal</i> , 2015 , 170, 419-29.e3	4.9	12
40	Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis. <i>American Heart Journal</i> , 2015 , 170, 96-103, 103.e1-14	4.9	14
39	Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension. <i>BMC Medical Research Methodology</i> , 2015 , 15, 34	4.7	21
38	Effect of macitentan on hospitalizations: results from the SERAPHIN trial. <i>JACC: Heart Failure</i> , 2015 , 3, 1-8	7.9	42
37	Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy. <i>Drug Design, Development and Therapy</i> , 2016 , 10, 3747-3754	4.4	9
36	Pharmacokinetics of drugs for pediatric pulmonary hypertension. <i>Pediatrics International</i> , 2016 , 58, 1112-1117	6	
35	In regard to Badiani and Messori, "Targeted Treatments for Pulmonary Arterial Hypertension: Interpreting Outcomes by Network Meta-analysis". <i>Heart Lung and Circulation</i> , 2016 , 25, 1137-1138	1.8	1

34	Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials. <i>Chest</i> , 2016 , 150, 353-66	5.3	32
33	An Update on the Management of Pulmonary Arterial Hypertension and the Pharmacist's Role. <i>Journal of Pharmacy Practice</i> , 2016 , 29, 67-76	1.3	9
32	The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , 2016 , 13, 842-9	4.7	22
31	Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2016 , 32, 1520-1530	3.8	39
30	Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 291-305	35.1	133
29	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. <i>Chest</i> , 2017 , 151, 468-480	5.9	57
28	Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. <i>Pulmonary Circulation</i> , 2017 , 7, 312-325	2.7	35
27	Incidence and risk of respiratory tract infection associated with specific drug therapy in pulmonary arterial hypertension: a systematic review. <i>Scientific Reports</i> , 2017 , 7, 16218	4.9	11
26	Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials. <i>Patient Preference and Adherence</i> , 2017 , 11, 871-885	2.4	12
25	Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial. <i>BMC Cardiovascular Disorders</i> , 2017 , 17, 239	2.3	19
24	Changing face of pulmonary arterial hypertension in Canada. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2017 , 1, 242-252	0.6	5
23	Trial Duration and Risk Reduction in Combination Therapy Trials for Pulmonary Arterial Hypertension: A Systematic Review. <i>Chest</i> , 2018 , 153, 1142-1152	5.3	3
22	Phosphodiesterase 5 inhibitors for pulmonary hypertension. <i>The Cochrane Library</i> , 2019 , 1, CD012621	5.2	32
21	The importance of right ventricular evaluation in risk assessment and therapeutic strategies: Raising the bar in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2020 , 301, 183-189	3.2	22
20	Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis. <i>International Journal of Rheumatic Diseases</i> , 2020 , 23, 1276-1287	2.3	1
19	Advanced Diagnosis and Therapy for Pulmonary Arterial Hypertension. <i>Nano LIFE</i> , 2020 , 10, 2040003	0.9	2
18	Endothelin receptor antagonists for pulmonary arterial hypertension. <i>The Cochrane Library</i> , 2021 , 3, CD014434	5.4	41
17	Pulmonary Hypertension. <i>Annals of Internal Medicine</i> , 2021 , 174, ITC49-ITC64	8	7

16	Echocardiography Monitoring of Pulmonary Hypertension after Pediatric Hematopoietic Stem Cell Transplantation: Pediatric Pulmonary Arterial Hypertension and Pulmonary Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 786.e1-786.e8		1
15	Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis. <i>Drug Delivery</i> , 2021 , 28, 1007-1019	7	2
14	The Modified Borg Dyspnea Scale does not predict hospitalization in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017 , 7, 384-390	2.7	5
13	Emerging role of cardiovascular magnetic resonance imaging in the management of pulmonary hypertension. <i>European Respiratory Review</i> , 2020 , 29,	9.8	10
12	Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats. <i>PLoS ONE</i> , 2018 , 13, e0195047	3.7	7
11	Updates on the Treatment of Pulmonary Hypertension. <i>Korean Journal of Medicine</i> , 2013 , 84, 346	0.5	
10	The Real World of Medical Treatment of Pulmonary Arterial Hypertension—Small Evidence, but Heavy Cornerstone— <i>Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery</i> , 2015 , 31, 157-183	0	
9	A meta-analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension. <i>Experimental and Therapeutic Medicine</i> , 2019 , 18, 4740-4746	2.1	1
8	Parenteral Prostacyclin Use in Pulmonary Arterial Hypertension. <i>Respiratory Medicine</i> , 2020 , 147-171	0.2	
7	Subgroup Analysis in Pulmonary Hypertension-Specific Therapy Clinical Trials: A Systematic Review. <i>Journal of Personalized Medicine</i> , 2022 , 12, 863	3.6	0
6	Effects of oral targeted treatments in pulmonary arterial hypertension: A systematic review and meta-analysis. 9,		
5	Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis. 2022 , 31, 220036		1
4	Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials. 2022 , 76, 102144		
3	Pulmonary pressure recovery in idiopathic, hereditary and drug and toxin-induced pulmonary arterial hypertension: determinants and clinical impact. 2022 , 146, 107099		1
2	The Evolving Management and Treatment Options for Patients with Pulmonary Hypertension: Current Evidence and Challenges. Volume 19, 103-126		0
1	Advances in the discovery of drugs that treat pulmonary arterial hypertension. 2023 , 18, 445-466		0